BPC-157

BPC-157, or Body Protection Compound 157, is an investigational 15-amino acid peptide often discussed for its purported tissue repair and "gut healing" properties. Despite widespread interest in wellness and gray markets, it lacks validated human safety data and an established mechanism of action, remaining unapproved by the FDA for any human medical use. The FDA has raised significant safety and evidence concerns regarding its use.

Identity and Structure

BPC-157 is a synthetic 15-amino acid peptide, commonly known as Body Protection Compound 157. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Other aliases listed by the FDA's Global Substance Registration System (GSRS) include Bepecin. It is described in primary literature as a stable gastric pentadecapeptide.

Proposed Mechanisms and Therapeutic Claims

While there is no validated human receptor target for BPC-157, preclinical studies suggest several potential mechanisms of action. These include pro-angiogenic signaling via the VEGFR2-Akt-eNOS pathway, nitric-oxide-mediated vasorelaxation, promotion of tendon fibroblast migration through FAK-paxillin, and increased growth hormone receptor expression in tendon fibroblasts. The primary claims associated with BPC-157, largely from preclinical research, involve musculoskeletal injury recovery, tendon/ligament healing, knee pain relief, "gut healing," and bladder pain/interstitial cystitis.

Evidence and Regulatory Status

The evidence supporting BPC-157's therapeutic claims in humans is minimal, consisting of very small, often uncontrolled, retrospective studies. There is no evidence-based mainstream off-label medical use. The FDA has not approved BPC-157 as a human drug component and explicitly flags it for safety and evidence concerns. These concerns include potential immunogenicity, peptide-related impurities, characterization complexity, serious adverse events, and a lack of adequate human safety data. BPC-157 is considered investigational and is frequently found in gray-market or wellness sectors, where it is not subject to the rigorous oversight required for approved pharmaceuticals.

Current Status

BPC-157 remains an investigational peptide with no FDA approval for any human medical use. Despite its presence in compounding and wellness markets, significant regulatory and scientific concerns persist regarding its safety, efficacy, and established mechanisms of action in humans. Further robust clinical research is needed to validate its purported benefits and ensure its safety.